Changes in Systolic and Diastolic Blood Pressure Following SGLT2 Therapy in Diabetic Patients with Kidney Impairment
Bilah Samping Artikel
Isi Artikel Utama
Abstrak
Background: Blood pressure reduction is an early hemodynamic response to sodium–glucose cotransporter-2 (SGLT2) inhibitors, although its magnitude varies among patients. This study evaluated clinical factors associated with blood pressure response following SGLT2 inhibitor therapy in patients with type 2 diabetes mellitus (T2DM) and kidney impairment. Methods: A retrospective cohort study was conducted using electronic medical records from two secondary healthcare centers. A total of 254 patients received SGLT2 inhibitor monotherapy (n=119), metformin monotherapy (n=124), or combination therapy (n=11). Demographic, clinical, laboratory, and blood pressure data were collected at baseline and follow-up. Blood pressure changes were assessed using the Wilcoxon signed-rank test and compared among treatment groups using the Kruskal–Wallis test. Spearman correlation and multiple linear regression were used to identify factors associated with ΔSBP and ΔDBP. Results: Median SBP decreased from 145.0 (IQR 27) to 129.5 (IQR 26) mmHg, with a median change of −15.5 mmHg (P<0.001). Median DBP decreased from 90.0 (IQR 16) to 80.0 (IQR 12) mmHg, with a median change of −10.0 mmHg (P<0.001). Greater blood pressure reductions were observed among patients receiving SGLT2 inhibitor monotherapy (both P<0.001). Age, diabetes duration, HbA1c change, and triglyceride change were associated with ΔSBP, while age and diabetes duration were associated with ΔDBP. Short-term eGFR changes were not independently associated with either outcome. Conclusions: SGLT2 inhibitor therapy was associated with reductions in blood pressure. Blood pressure response was associated mainly with patient-specific clinical and metabolic characteristics rather than short-term changes in kidney function.
Rincian Artikel
Artikel ini berlisensiCreative Commons Attribution-ShareAlike 4.0 International License.
Referensi
Beernink, J. M., Jongs, N., Mosterd, C. M., Scholtes, R. A., Caldwell‐McGee, A., Casillas, D., Driscoll, L., Greasley, P. J., Karlsson, C., Hammarstedt, A., Sridhar, V. S., Muskiet, M. H. A., Laverman, G. D., Cherney, D. Z. I., Bjornstad, P., van Raalte, D. H., & Heerspink, H. J. L. (2025). Effects of dapagliflozin on sodium excretion, blood pressure and volume status in patients with type 2 diabetes and/or chronic kidney disease: The DAPASALT trial. Diabetes, Obesity and Metabolism, 27(8), 4415–4426. https://doi.org/10.1111/dom.16478
Chertow, G. M., Vart, P., Jongs, N., Toto, R. D., Gorriz, J. L., Hou, F. F., McMurray, J. J. V., Correa-Rotter, R., Rossing, P., Sjöström, C. D., Stefánsson, B. V., Langkilde, A. M., Wheeler, D. C., & Heerspink, H. J. L. (2021). Effects of Dapagliflozin in Stage 4 Chronic Kidney Disease. Journal of the American Society of Nephrology, 32(9), 2352–2361. https://doi.org/10.1681/ASN.2021020167
ElSayed, N. A., McCoy, R. G., Aleppo, G., Bajaj, M., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., Ekhlaspour, L., Gaglia, J. L., Garg, R., Girotra, M., Khunti, K., Lal, R., Lingvay, I., Matfin, G., Neumiller, J. J., Pandya, N., … Bannuru, R. R. (2025a). 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025. Diabetes Care, 48(Supplement_1), S181–S206. https://doi.org/10.2337/dc25-S009
ElSayed, N. A., McCoy, R. G., Aleppo, G., Bajaj, M., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., Ekhlaspour, L., Gaglia, J. L., Garg, R., Girotra, M., Khunti, K., Lal, R., Lingvay, I., Matfin, G., Neumiller, J. J., Pandya, N., … Bannuru, R. R. (2025b). 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025. Diabetes Care, 48(Supplement_1), S181–S206. https://doi.org/10.2337/dc25-S009
Empagliflozin in Patients with Chronic Kidney Disease. (2023). New England Journal of Medicine, 388(2), 117–127. https://doi.org/10.1056/NEJMoa2204233
Heerspink, H. J., Provenzano, M., Vart, P., Jongs, N., Correa-Rotter, R., Rossing, P., Mark, P. B., Pecoits-Filho, R., McMurray, J. J., Langkilde, A. M., Wheeler, D. C., Toto, R. B., & Chertow, G. M. (2024). Dapagliflozin and Blood Pressure in Patients with Chronic Kidney Disease and Albuminuria. American Heart Journal, 270, 125–135. https://doi.org/10.1016/j.ahj.2024.02.006
Inzucchi, S. E., Davies, M. J., Khunti, K., Trivedi, P., George, J. T., Zwiener, I., Johansen, O. E., & Sattar, N. (2021). Empagliflozin treatment effects across categories of baseline HbA1c , body weight and blood pressure as an add‐on to metformin in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 23(2), 425–433. https://doi.org/10.1111/dom.14234
Iqbal, F., Shuja, M. H., Azam, L., Amjad, M., Manjee, K. Z., Ramzan, H., Sharif, T., Shoaib, A., Tahir, A., Kumar, S., Khatri, M., Varrassi, G., & Mohamad, T. (2024). Effect of Sodium-Glucose Cotransporter 2 Inhibitors on the 24-Hour Ambulatory Blood Pressure in Patients With Type 2 Diabetes Mellitus and Hypertension: An Updated Meta-Analysis. Endocrine Practice, 30(5), 481–489. https://doi.org/10.1016/j.eprac.2024.03.001
Lim, R. P., Qassin, S., McKenna, L., Hornsey, E., Italiano, D., Churilov, L., MacIsaac, R. J., Seah, J., & Ekinci, E. I. (2026). Multi‐Parametric Magnetic Resonance Imaging to Assess Empagliflozin Effect on the Kidneys in People With Type 2 Diabetes Mellitus: A Pilot Clinical Trial. Diabetes, Obesity and Metabolism, 28(8), 7416–7429. https://doi.org/10.1111/dom.70950
McEwan, P., Gabb, P. D., Davis, J. A., Garcia Sanchez, J. J., Sjöström, C. D., Barone, S., Kashioulis, P., Ouwens, M., Cassimaty, S., Correa-Rotter, R., Rossing, P., Wheeler, D. C., & Heerspink, H. J. L. (2024). The long-term effects of dapagliflozin in chronic kidney disease: a time-to-event analysis. Nephrology Dialysis Transplantation, 39(12), 2040–2047. https://doi.org/10.1093/ndt/gfae106
Okada, K., Hoshide, S., Kato, M., Kanegae, H., Ishibashi, S., & Kario, K. (2021). Safety and efficacy of empagliflozin in elderly Japanese patients with type 2 diabetes mellitus: A post hoc analysis of data from the SACRA study. The Journal of Clinical Hypertension, 23(4), 860–869. https://doi.org/10.1111/jch.14131
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., Cannon, C. P., Capuano, G., Chu, P.-L., de Zeeuw, D., Greene, T., Levin, A., Pollock, C., Wheeler, D. C., Yavin, Y., … Mahaffey, K. W. (2019). Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. New England Journal of Medicine, 380(24), 2295–2306. https://doi.org/10.1056/NEJMoa1811744
Scholtes, R. A., Mosterd, C. M., Hesp, A. C., Smits, M. M., Heerspink, H. J. L., & van Raalte, D. H. (2023). Mechanisms underlying the blood pressure‐lowering effects of empagliflozin, losartan and their combination in people with type 2 diabetes: A secondary analysis of a randomized crossover trial. Diabetes, Obesity and Metabolism, 25(1), 198–207. https://doi.org/10.1111/dom.14864
Stevens, P. E., Ahmed, S. B., Carrero, J. J., Foster, B., Francis, A., Hall, R. K., Herrington, W. G., Hill, G., Inker, L. A., Kazancıoğlu, R., Lamb, E., Lin, P., Madero, M., McIntyre, N., Morrow, K., Roberts, G., Sabanayagam, D., Schaeffner, E., Shlipak, M., … Levin, A. (2024). KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney International, 105(4), S117–S314. https://doi.org/10.1016/j.kint.2023.10.018
Tikkanen, I., Narko, K., Zeller, C., Green, A., Salsali, A., Broedl, U. C., & Woerle, H. J. (2015). Empagliflozin Reduces Blood Pressure in Patients With Type 2 Diabetes and Hypertension. Diabetes Care, 38(3), 420–428. https://doi.org/10.2337/dc14-1096
Yu, M. K., Vart, P., Jongs, N., Correa-Rotter, R., Rossing, P., McMurray, J. J. V., Hou, F.-F., Douthat, W., Khullar, D., Langkilde, A. M., Wheeler, D. C., Heerspink, H. J. L., & Chertow, G. M. (2024). Effects of Dapagliflozin in Chronic Kidney Disease Across the Spectrum of Age and by Sex. Journal of General Internal Medicine, 39(6), 921–930. https://doi.org/10.1007/s11606-023-08397-9
Zou, X., Shi, Q., Olav Vandvik, P., Mao, Y., Agarwal, A., Ponte, B., Zeng, X., Guyatt, G., Yang, Q., Luo, X., Xu, C., Fu, P., Tian, H., Agoritsas, T., & Li, S. (2024). Sodium-glucose co-transporter-2 inhibitors in patients with chronic kidney disease with or without type 2 diabetes: systematic review and meta-analysis. BMJ Medicine, 3(1), e001009. https://doi.org/10.1136/bmjmed-2024-001009